HWPC(688799)2024-12-30 07:33Group 1: Drug Development Progress - ZG-002 is a new drug developed by Shanghai Zhigen Pharmaceutical Technology Co., Ltd. for the treatment of moderate to severe plaque psoriasis, currently in Phase I clinical trials [1] - ZG-001 capsule shows good safety in Phase I clinical trials, with no severe adverse reactions reported [4] - Qianqing Granules, an innovative traditional Chinese medicine, has completed Phase II clinical trials [1] Group 2: Company Holdings and Collaborations - The company holds a 40% stake in Zhigen Pharmaceutical [1] - The company collaborates with Hunan Tianji Rare Chinese Medicinal Materials Development Co., Ltd. and the Chinese Academy of Medical Sciences for the development of artificial substitutes for endangered animal medicinal materials, currently in preclinical research [4] Group 3: Regulatory and Market Strategies - The company actively participates in national centralized procurement, with four products successfully winning bids [5] - The National Medical Products Administration has issued guidelines for the development of substitutes for endangered medicinal materials, requiring at least Phase III clinical trials for comparative studies [4][8]